BioTelemetry (BEAT) Tops Q3 EPS by 21c; Raises Outlook

BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.53, $0.21 better than the analyst estimate of $0.32. Revenue for the quarter came in at $100 million versus the consensus estimate of $97.92 million.

GUIDANCE:

BioTelemetry sees FY2018 revenue of $397-400 million, versus the consensus of $394.2 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance